| Gene symbol | PSCA | Synonyms | PRO232, lncPSCA | Type of gene | protein-coding |
| Chromosome | 8 | Map location | 8q24.3 | dbXrefs | |
| Description | prostate stem cell antigen | ||||
| GTO ID | GTC0766 |
| Trial ID | ChiCTR1800018277 |
| Disease | Prostate Cancer |
| Altered gene | PSCA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | PSCA CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Safety and efficacy of autologous PSCA-CAR-T cells immunotherapy for castration resistant prostate cancer: a A phase I & phase II study |
| Year | 2018 |
| Country | China |
| Company sponsor | Hebei General Hospital |
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||
| Cohort3: dose level 3 | |||||||||
|
|||||||||
| Cohort4: dose level 4 | |||||||||
|
|||||||||